ArticleNature communications2025
Fishing out AIEC with FimH capturing microgels for inflammatory bowel disease treatment.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Current and emerging therapeutic strategies targeting adherent-invasive Escherichia coli in Crohn's disease: a review.Gut pathogens · 2026Review
- From inflammation to fibrosis and cancer: the emerging role of AIEC-derived metabolites in intestinal disease progression.Experimental & molecular medicine · 2026Review
- Gut microbiota dysbiosis and the gut-lung axis in COPD: mechanisms, clinical relevance, and microbiota-targeted interventions.Frontiers in cell and developmental biology · 2026Review
- Macrophages in Ulcerative Colitis: Immunomodulatory Roles, Phenotypic Switching, and Therapeutic Targeting.Journal of innate immunity · 2026Review
- Mannans as Multifunctional Biopolymers: Structure, Properties, and Applications in Health and Industry.Polymers · 2025Review
- Fabrication of Single-Bacterium Microgel with Gas-Shearing Strategy for Precision Probiotic Delivery in IBD Therapy.Research (Washington, D.C.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is a chronic immune-mediated condition with rising global incidence and limited treatment options. Current therapies often have poor efficacy and undesirable side effects. Here we present a drug-free strategy that targets bacterial adhesion to manage IBD. We develop porous microgels loaded with mannan oligosaccharides (MOS) that mimic the natural binding sites of intestinal cells. These microgels attract adherent-invasive Escherichia coli (AIEC) by interacting with FimH, a bacterial protein used for attachment, thereby preventing AIEC from colonizing the gut lining. The microgels are fabricated using an all-aqueous two-phase system, enabling biocompatibility and structural control. In a mouse model of IBD, this competitive adsorption approach alleviates intestinal inflammation, reduces harmful Enterobacteriaceae, and enhances gut microbial diversity. This work introduces a non-antibiotic, bioinspired method that intercepts pathogenic bacteria and restores microbial balance, offering a promising therapeutic strategy for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.